How fast is the rate of weight loss on Wegovy, and what should you realistically expect?

You're three weeks in, the scales have barely moved, and you're wondering whether something is wrong

This is probably the most common worry our prescribers hear in the early weeks of treatment. The 0.25mg starting dose exists primarily to help your body adjust, reducing the chance of nausea and other gastrointestinal discomfort during the settling-in period. It is not a therapeutic weight-loss dose, and expecting dramatic changes at this stage sets an unfair benchmark. Most people see only modest movement on the scales in the first four to eight weeks, and some see none at all. That is not a sign the medicine is failing.

What tends to happen as the dose increases is that appetite suppression becomes more pronounced, portion sizes naturally fall, and the body begins drawing on stored energy more consistently. What happens in week one on Wegovy covers the very early phase in more detail, but the short version is: the first pen's job is adjustment, not transformation.

One misconception worth gently setting aside is the idea that Wegovy causes rapid, dramatic drops in weight from day one. The trial data does not support this picture. In the STEP 1 study, participants had lost around 5–6% of their body weight by week 20, with the steeper portion of the curve arriving later, once the full dose was established. Steady, sustained loss over many months is the actual pattern.

How the rate of loss shifts through the titration schedule

Semaglutide 2.4mg is reached through a step-up schedule, doses increase roughly every four weeks, from 0.25mg through 0.5mg, 1mg and 1.7mg before reaching the 2.4mg maintenance dose. The NHS medicines page for semaglutide describes the schedule factually; the exact timing for any individual is a decision made with the prescriber, not self-directed.

What tends to happen in practice is that the rate of weekly weight loss accelerates during this titration period and reaches its fastest pace in roughly months four to six, when the maintenance dose has been active for several weeks. After that, the rate typically slows as the body adapts. By months twelve to eighteen, many people's weight loss has plateaued or become very gradual. This is physiologically normal and does not mean the medicine has stopped working, maintaining a significant loss at this stage still represents a meaningful health outcome.

If you are not seeing the progress you expected, what to do if Wegovy does not seem to be working addresses the common reasons and what a prescriber would consider next.

How the newer 7.2mg dose changes the expected rate of loss

The MHRA approved a higher 7.2mg maintenance dose of semaglutide in January 2026, and approved a dedicated single-dose 7.2mg pen in April 2026. Trial data for this dose reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide (Mounjaro) at its highest dose. The titration pathway still begins at 0.25mg, so the overall timeline before reaching the higher maintenance dose is longer, and the maximum dose is reached by clinical assessment, not by default.

This development matters for understanding the rate question because it means the ceiling has risen. For people who tolerate semaglutide well and whose prescriber progresses them to 7.2mg, the eventual total loss and the rate of loss in months eight to eighteen may be meaningfully greater than earlier trial figures suggested. That said, these are average outcomes from controlled trials, individual variation remains significant. How long it takes to see results on Wegovy explores the timeline in more practical terms.

For a broader look at where Wegovy sits within the treatment landscape (and how cost fits into the picture) Wegovy pricing and what it includes gives a straightforward overview of the private prescription route.

What determines your personal rate of loss

Trial averages are population figures. Your individual rate will be shaped by factors that no trial can fully account for. Starting weight matters: someone beginning at a higher BMI often sees larger absolute losses early on. Metabolic rate, sleep, stress, physical activity and the degree to which appetite suppression translates into reduced calorie intake all play a role. Genetics also appear to influence how strongly any individual responds to GLP-1 receptor agonists, though this is still an active area of research.

The overall Wegovy weight loss guide covers the lifestyle factors that the evidence suggests complement treatment most effectively. The short version: adequate protein, regular movement (including resistance exercise where possible), and close contact with a clinical team throughout.

If you would like to understand whether Wegovy is clinically suitable for your situation, speaking to our prescribers is the straightforward next step. Every consultation at nume is reviewed by a GPhC-registered Independent Prescriber, assessed the same day, and carried out with no subscription commitment.